Sofia Verkhovskaia

Rome, 00167, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Immune-Related Adverse Events in Patients with Melanoma Treated with B-RAF/MEK Target Therapy: Occurrence and Circulating Immune Cell Analysis.

Immune-Related Adverse Events in Patients with Melanoma Treated with B-RAF/MEK Target Therapy: Occurrence and Circulating Immune Cell Analysis.

Journal: Cancers

Published: February 10, 2026

Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of Patients.

Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of Patients.

Journal: Acta dermato-venereologica

Published: January 09, 2026

Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of Patients.

Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of Patients.

Journal: Acta dermato-venereologica

Published: January 09, 2026

Case Report: The role of BRAF mutation in adjuvant and neoadjuvant treatment of melanoma patients: what is the optimal approach?

Case Report: The role of BRAF mutation in adjuvant and neoadjuvant treatment of melanoma patients: what is the optimal approach?

Journal: Frontiers in oncology

Published: December 25, 2025

The role of the molecular tumor board: learnings from the ROME trial.

The role of the molecular tumor board: learnings from the ROME trial.

Journal: NPJ precision oncology

Published: November 18, 2025

Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.

Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.

Journal: Frontiers in pharmacology

Published: October 02, 2025

Application of Radiomics in Melanoma: A Systematic Review and Meta-Analysis.

Application of Radiomics in Melanoma: A Systematic Review and Meta-Analysis.

Journal: Cancers

Published: August 04, 2025

Impact of Drug-Drug Interactions on Clinical Outcomes in Metastatic Melanoma Patients Treated With Combined BRAF/MEK Inhibitors: A Real-World Study.

Impact of Drug-Drug Interactions on Clinical Outcomes in Metastatic Melanoma Patients Treated With Combined BRAF/MEK Inhibitors: A Real-World Study.

Journal: Pigment cell & melanoma research

Published: April 22, 2025

The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial.

The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 04, 2025

Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial.

Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial.

Journal: Nature medicine

Published: December 27, 2024

Weekly carboplatin plus paclitaxel chemotherapy in advanced melanoma patients resistant to anti-PD-1 inhibitors: a retrospective, monocentric experience.

Weekly carboplatin plus paclitaxel chemotherapy in advanced melanoma patients resistant to anti-PD-1 inhibitors: a retrospective, monocentric experience.

Journal: BMC cancer

Published: August 05, 2024

Survival of Patients with Metastatic Melanoma Treated with Ipilimumab after PD-1 Inhibitors: A Single-Center Real-World Study.

Survival of Patients with Metastatic Melanoma Treated with Ipilimumab after PD-1 Inhibitors: A Single-Center Real-World Study.

Journal: Cancers

Published: August 05, 2024

Showing 1-12 of 21

Last Updated: 09/26/2026